Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29328229 | 0.76 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL25213075 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL5035685 | 0.73 | HTR4 (0.41) | MAPK1 | |
| SCHEMBL30364014 | 0.72 | MAPKAPK2 (0.36) | MAPK1 | |
| SCHEMBL23363821 | 0.72 | MAPKAPK2 (0.36) | MAPK1 | |
| SCHEMBL25260111 | 0.72 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL23363869 | 0.70 | MAPT (0.36) | MAPK1 | |
| SCHEMBL18181775 | 0.69 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL31135900 | 0.67 | — | — | |
| SCHEMBL20424920 | 0.67 | XDH (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | MAPK1 4365/4885HTR2A 3460/4885HTR2C 2898/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | MAPK1 4365/4885HTR2A 3460/4885HTR2C 2898/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | MAPK1 4365/4885HTR2A 3460/4885HTR2C 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.